Skip to content

Pharmacy Implementation Trial: Adherence to Antihypertensive Therapy

Implementation of a Pharmacy-Intervention to Establish and if Necessary Improve Adherence to Antihypertensive Therapy. A Cluster Randomized Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00460343
Enrollment
57
Registered
2007-04-13
Start date
2007-04-30
Completion date
2008-06-30
Last updated
2008-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

patient non-adherence, antihypertensive agents, community pharmacy services, professional roles

Brief summary

The purpose of this study is to determine the effectiveness of maximal support of community pharmacies to implement a pharmaceutical care model for establishing and - if necessary - improving adherence to antihypertensive medication in patients with medication-resistant hypertension.

Detailed description

Cardiovascular disease is the main cause of death in large parts of the world. Hypertension is an important risk factor for cardiovascular disease. Although hypertension treatment has improved in the last decade, the effectiveness of antihypertensive therapy still needs attention. Adherence to medication appears to play an important role in that. Pharmacists can support the general practitioners in their efforts to optimize antihypertensive therapy, by establishing adherence to medication of patients with hypertension in spite of the use of one or more antihypertensive drugs. This is performed with the electronic Medication Event Monitoring System (MEMS®). Registered adherence and accompanying blood pressure are discussed with the patient by the GP. Implementation of the above-mentioned intervention is studied in two randomized groups of pharmacies. One group receives minimal support in the intervention, the other group also receives interactive educational meetings, reminders and feedback, and support of multiprofessional cooperation.

Interventions

OTHERextensive implementation programme

experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.

OTHERcontrol

pharmacists only receive a written manual with instructions to implement the patient compliance intervention.

Sponsors

Zorgverzekeraar CZ
CollaboratorOTHER
Scientific Institute for Dutch Pharmacists, The Netherlands
CollaboratorOTHER
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* pharmacies: resident in the south of the Netherlands * patients: * 18 years or older * diagnosis of hypertension * systolic blood pressure between 150 and 180 mm Hg despite the use of antihypertensive drug(s) * indication for treatment escalation

Exclusion criteria

* patients: * impossibility to establish blood pressure properly * patient treated by medical specialist * change of antihypertensive therapy because of adverse effects of current medication * insisting on using dose organisers * not managing their drug intake themselves * not able to come to the pharmacy

Design outcomes

Primary

MeasureTime frame
the number of patients included for intervention9 months after start of the study

Secondary

MeasureTime frame
improvement of systolic blood pressure2 and 5 months after inclusion
treatment escalation of patients after inclusion into the study5 months after inclusion
the percentage of GP's in PTAM that cooperates in the intervention9 months after start of the study

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026